- Home
- DXR vs PLRX Comparison
DXR vs PLRX Comparison
Compare DXR & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXR | PLRX |
|---|---|---|
| Founded | 1970 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.0M | 61.1M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DXR | PLRX |
|---|---|---|
| Price | $10.05 | $0.90 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 6 |
| Target Price | ★ $20.00 | $2.67 |
| AVG Volume (30 Days) | 15.0K | ★ 373.0K |
| Earning Date | 11-13-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,446,345.00 | N/A |
| Revenue This Year | $44,489.33 | N/A |
| Revenue Next Year | $74.79 | N/A |
| P/E Ratio | $33.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.56 | $0.88 |
| 52 Week High | $14.76 | $1.95 |
Technical Indicators
Market Signals| Indicator | DXR | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.18 | 33.98 |
| Support Level | $9.38 | N/A |
| Resistance Level | $10.99 | $1.37 |
| Average True Range (ATR) | 0.49 | 0.05 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 5.24 | 6.01 |
Price Performance
Historical ComparisonAbout DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.